5-Hydroxytryptamine Receptors and Tardive Dyskinesia in Schizophrenia

5-Hydroxytryptamine Receptors and Tardive Dyskinesia in Schizophrenia

BackgroundTardive dyskinesia (TD) is a common side effect of antipsychotic treatment. This movement disorder consists of orofacial and limb-truncal components. The present study is aimed at investigating the role of serotonin receptors (HTR) in modulating tardive dyskinesia by genotyping patients wi...

Full description

Bibliographic Details
Main Authors:	Ivan V. Pozhidaev, Diana Z. Paderina, Olga Yu. Fedorenko, Elena G. Kornetova, Arkadiy V. Semke, Anton J. M. Loonen, Nikolay A. Bokhan, Bob Wilffert, Svetlana A. Ivanova
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2020-04-01
Series:	Frontiers in Molecular Neuroscience
Subjects:	schizophrenia tardive dyskinesia 5-HT receptors pharmacogenetics gene polymorphisms
Online Access:	https://www.frontiersin.org/article/10.3389/fnmol.2020.00063/full

Similar Items

Genes of the Glutamatergic System and Tardive Dyskinesia in Patients with Schizophrenia
by: Olga Yu. Fedorenko, et al.
Published: (2022-06-01)

Association of Cholinergic Muscarinic M4 Receptor Gene Polymorphism with Schizophrenia
by: Pozhidaev IV, et al.
Published: (2020-04-01)

Limited Associations Between 5-HT Receptor Gene Polymorphisms and Treatment Response in Antidepressant Treatment-Free Patients With Depression
by: Taichi Ochi, et al.
Published: (2019-12-01)

Genetic Polymorphisms of <i>5-HT</i> Receptors and Antipsychotic-Induced Metabolic Dysfunction in Patients with Schizophrenia
by: Diana Z. Paderina, et al.
Published: (2021-03-01)

Gene Polymorphisms of Hormonal Regulators of Metabolism in Patients with Schizophrenia with Metabolic Syndrome
by: Anastasiia S. Boiko, et al.
Published: (2022-05-01)

Preliminary Pharmacogenetic Study to Explore Putative Dopaminergic Mechanisms of Antidepressant Action
by: Taichi Ochi, et al.
Published: (2021-07-01)

A pharmacogenetic study of patients with schizophrenia from West Siberia gets insight into dopaminergic mechanisms of antipsychotic-induced hyperprolactinemia
by: Diana Z. Osmanova, et al.
Published: (2019-04-01)

The Gender-Specific Association of DRD2 Polymorphism with Metabolic Syndrome in Patients with Schizophrenia
by: Diana Z. Paderina, et al.
Published: (2022-07-01)

The Role of Glutamatergic Gene Polymorphisms in the Clinical Phenotypes of Schizophrenia
by: Evgeniya G. Poltavskaya, et al.
Published: (2023-02-01)

Search for Possible Associations of FTO Gene Polymorphic Variants with Metabolic Syndrome, Obesity and Body Mass Index in Schizophrenia Patients
by: Boiko AS, et al.
Published: (2021-09-01)

Changes in Body Fat and Related Biochemical Parameters Associated With Atypical Antipsychotic Drug Treatment in Schizophrenia Patients With or Without Metabolic Syndrome
by: Elena G. Kornetova, et al.
Published: (2019-11-01)

<i>NOS1AP</i> Gene Variants and Their Role in Metabolic Syndrome: A Study of Patients with Schizophrenia
by: Irina A. Mednova, et al.
Published: (2024-03-01)

Study of Early Onset Schizophrenia: Associations of <i>GRIN2A</i> and <i>GRIN2B</i> Polymorphisms
by: Evgeniya G. Poltavskaya, et al.
Published: (2021-09-01)

Genetic polymorphisms of PIP5K2A and course of schizophrenia
by: Evgeniya G. Poltavskaya, et al.
Published: (2020-10-01)

Association Between BDNF Gene Variant Rs6265 and the Severity of Depression in Antidepressant Treatment-Free Depressed Patients
by: Innokentiy S. Losenkov, et al.
Published: (2020-02-01)

Apolipoprotein serum levels related to metabolic syndrome in patients with schizophrenia
by: Anastasiia S. Boiko, et al.
Published: (2019-07-01)

Likelihood of mechanistic roles for dopaminergic, serotonergic and glutamatergic receptors in tardive dyskinesia: A comparison of genetic variants in two independent patient populations
by: Svetlana A Ivanova, et al.
Published: (2016-04-01)

Polymorphisms of Catechol-O-Methyl Transferase (COMT) Gene in Vulnerability to Levodopa-Induced Dyskinesia
by: Svetlana A. Ivanova, et al.
Published: (2018-08-01)

NRG1, PIP4K2A, and HTR2C as Potential Candidate Biomarker Genes for Several Clinical Subphenotypes of Depression and Bipolar Disorder
by: Anastasia Levchenko, et al.
Published: (2020-08-01)

Adipocytokines and Metabolic Syndrome in Patients with Schizophrenia
by: Irina A. Mednova, et al.
Published: (2020-10-01)

Association of <i>PIP4K2A</i> Polymorphisms with Alcohol Use Disorder
by: Olga Yu. Fedorenko, et al.
Published: (2021-10-01)

Lep gene and leptin concentration in serum of schizophrenia patients with metabolic syndrome
by: A. Boiko, et al.
Published: (2021-04-01)

Putative role of immune reactions in the mechanism of tardive dyskinesia
by: Anton J.M. Loonen
Published: (2023-11-01)

Cytokines as Potential Biomarkers of Clinical Characteristics of Schizophrenia
by: Irina A. Mednova, et al.
Published: (2022-11-01)

Cell Adhesion Molecules in Schizophrenia Patients with Metabolic Syndrome
by: Anastasiia S. Boiko, et al.
Published: (2023-03-01)

Cortisol and DHEAS Related to Metabolic Syndrome in Patients with Schizophrenia
by: Boiko AS, et al.
Published: (2020-04-01)

Serum Growth Factors in Schizophrenia Patients
by: Anastasiia S. Boiko, et al.
Published: (2023-04-01)

Association of rs11644461 GRIN2A with clinical phenotype of schizophrenia
by: E. Poltavskaya, et al.
Published: (2023-03-01)

A New Paradigm to Indicate Antidepressant Treatments
by: Anton J. M. Loonen, et al.
Published: (2021-12-01)

Metabolic Hormones in Schizophrenia Patients with Antipsychotic-Induced Metabolic Syndrome
by: Anastasiia S. Boiko, et al.
Published: (2022-10-01)

Cytokine Level Changes in Schizophrenia Patients with and without Metabolic Syndrome Treated with Atypical Antipsychotics
by: Anastasiia S. Boiko, et al.
Published: (2021-05-01)

Association of СОМТ gene polymorphisms with Parkinson’s disease
by: Svetlana A. Ivanova, et al.
Published: (2017-10-01)

Levels of Acylcarnitines and Branched-Chain Amino Acids in Antipsychotic-Treated Patients with Paranoid Schizophrenia with Metabolic Syndrome
by: Irina A. Mednova, et al.
Published: (2022-09-01)

Body Fat Parameters, Glucose and Lipid Profiles, and Thyroid Hormone Levels in Schizophrenia Patients with or without Metabolic Syndrome
by: Elena G. Kornetova, et al.
Published: (2020-09-01)

The functional variant rs334558 of GSK3B is associated with remission in patients with depressive disorders
by: Levchenko A, et al.
Published: (2018-07-01)

Amino Acid and Acylcarnitine Levels in Chronic Patients with Schizophrenia: A Preliminary Study
by: Irina A. Mednova, et al.
Published: (2021-01-01)

Drug-induced metabolic syndrome hasn’t associations with 5-HT receptor genes polymorphisms in patients with schizophrenia
by: D. Paderina, et al.
Published: (2021-04-01)

Tardive dyskinesia
by: Violetta A. Tolmacheva
Published: (2021-11-01)

Drug-induced tardive dyskinesia
by: T. M. Ostroumova, et al.
Published: (2020-02-01)

Building Predictive Models for Schizophrenia Diagnosis with Peripheral Inflammatory Biomarkers
by: Evgeny A. Kozyrev, et al.
Published: (2023-07-01)